Immutep Limited (NASDAQ:IMMP - Get Free Report)'s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.69 and traded as low as $1.67. Immutep shares last traded at $1.71, with a volume of 59,004 shares traded.
Immutep Trading Down 18.5 %
The company has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $1.89. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01.
Institutional Trading of Immutep
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. OLD Mission Capital LLC acquired a new stake in Immutep during the 4th quarter worth approximately $36,000. Two Sigma Securities LLC bought a new stake in shares of Immutep during the 4th quarter worth about $74,000. Fortitude Advisory Group L.L.C. bought a new stake in shares of Immutep in the fourth quarter valued at about $28,000. ABC Arbitrage SA acquired a new stake in Immutep during the fourth quarter worth approximately $152,000. Finally, XY Capital Ltd lifted its holdings in shares of Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 56,306 shares during the period. Institutional investors and hedge funds own 2.32% of the company's stock.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Stories
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
